⌕
Stoke Therapeutics · STOK · Nasdaq
Tenet 50 · Mixed
Compare
$26.41−0.83%At closeTenet 50 · Mixed
$26.41−0.22 (−0.83%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Stoke Therapeutics (STOK) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

46 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~145.9%/yr (FY22→FY25), net margin −3.7%. Worth your attention in FY25: Share count (+61.2%) and Capex step-up ($670.0K). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲404.5%
184.4
FY22→FY25CAGR +145.9%/yr
Net income ($M)▲92.3%
−6.9
FY21→FY25CAGR —
Free cash flow ($M)—
44.9
capex stepped upCAGR —
Diluted EPS▲92.7%
−0.12
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+61.2%

36.7mn → 59.2mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$670.0K

▲230% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)184.4Revenue0.0COGS−137.9R&D−67.1SG&A−20.6Op income13.7Tax & other−6.9Net income

-4¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Operating Net
108530%sector median net margin ~3%FY21FY25

Net margin -3.7% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
28,211.0184,420.036,555.08,780.012,405.00.0▲404.5%+145.9% (22→25)
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—A—A—A—A—A0.0——
Research & development
190,700.0137,922.089,133.082,231.077,837.054,168.0▲54.7%+26.3%
Selling, general & admin
95,112.067,088.048,794.041,322.038,924.031,897.0▲37.5%+20.4%
Total operating expenses
285,812.0205,010.0137,927.0123,553.0116,761.086,065.0▲48.6%+24.2%
Operating incomefeeds ROC rank
−257,601.0−20,590.0−101,372.0−114,773.0−104,356.0−86,065.0▲79.7%—
Other income, net
14,402.013,705.012,391.010,074.03,289.0260.0——
Pretax income
−243,199.0−6,885.0−88,981.0−104,699.0−101,067.0−85,805.0▲92.3%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−243,199.0−6,885.0−88,981.0−104,699.0−101,067.0−85,805.0▲92.3%—
Per share
Diluted EPSbuyback-sensitive
−3.77−0.12−1.65−2.38−2.60−2.34▲92.7%—
Diluted shares (mn)
68.3659.2254.0143.9938.9036.74▲9.6%+12.7%
Margins
Gross margin
—A—A—A—A—A———
Operating margin
−913.1%−11.2%−277.3%−1307.2%−841.2%—▲266.1pp+830.1pp
Net margin2nd pct in Healthcare
−862.1%−3.7%−243.4%−1192.5%−814.7%—▲239.7pp+811.0pp
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY18 – FY20 · 3 more years
Unlock the full history →
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-16 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Stoke Therapeutics' revenue last fiscal year?

Stoke Therapeutics reported revenue of $184.4M in fiscal 2025, up 404.5% from fiscal 2024.

What was Stoke Therapeutics' net income?

Stoke Therapeutics reported net income of −$6.9M in fiscal 2025, a net margin of −3.7%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.